Optimal biologics for juvenile idiopathic arthritis in an infection with SARS-CoV-2 α-variant
- PMID: 34741565
- PMCID: PMC8646268
- DOI: 10.1111/pai.13686
Optimal biologics for juvenile idiopathic arthritis in an infection with SARS-CoV-2 α-variant
Keywords: COVID-19; juvenile idiopathic arthritis; tocilizumab.
Conflict of interest statement
The authors have declared no conflicts of interest.
References
-
- Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID‐19 in patients with rheumatic diseases? Ann Rheumat Dis. 2021;80:1. - PubMed
-
- Aydın F, Çelikel E, Ekici Tekin Z, et al. Comparison of baseline laboratory findings of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis and multisystem inflammatory syndrome in children. Int J Rheum Dis. 2021;24:542‐547. - PubMed
-
- Demir F, Ulu K, Çağlayan Ş, Coşkuner T, Sözeri B. Clinical course of COVID‐19 in children with rheumatic disease under biologic therapy. Clin Exp Rheumatol. 2021;39 Suppl 128(1):36‐37. - PubMed
-
- Yildiz M, Haslak F, Adrovic A, et al. The frequency and clinical course of COVID‐19 infection in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2020;38:1271‐1272. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical